Elimination of Minimal Residual Disease After Transplant
Summary
Third Opinion Trial Synopsis:
This study is for patients with a type of cancer called multiple myeloma. The patients in the study have leftover cancer cells in their bone marrow after a certain type of treatment. The study will only have patients from one hospital and will test a new treatment.
This study is for patients with a type of cancer called multiple myeloma. The patients in the study have leftover cancer cells in their bone marrow after a certain type of treatment. The study will only have patients from one hospital and will test a new treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: